Assessment of Safety and Probiotic Traits of \textit{Enterococcus durans} OSY-EGY, Isolated From Egyptian Artisanal Cheese, Using Comparative Genomics and Phenotypic Analyses

Walaa E. Hussein\textsuperscript{1,2}, Ahmed G. Abdelhamid\textsuperscript{1,3}, Diana Rocha-Mendoza\textsuperscript{1}, Israel García-Cano\textsuperscript{1} and Ahmed E. Yousef\textsuperscript{1,4}\*  

\textsuperscript{1} Department of Food Science and Technology, The Ohio State University, Columbus, OH, United States, \textsuperscript{2} Department of Microbiology and Immunology, National Research Center, Giza, Egypt, \textsuperscript{3} Botany and Microbiology Department, Faculty of Science, Benha University, Benha, Egypt, \textsuperscript{4} Department of Microbiology, The Ohio State University, Columbus, OH, United States

An \textit{Enterococcus durans} strain, designated OSY-EGY, was previously isolated from artisanal cheese. In this work, comparative genomic and phenotypic analyses were utilized to assess the safety characteristics and probiotic traits of the bacterium. The comparative genomic analysis revealed that the strain is distantly related to potentially pathogenic \textit{Enterococcus} spp. The genome was devoid of genes encoding acquired antibiotic resistance or marker virulence factors associated with \textit{Enterococcus} spp. Phenotypically, the bacterium is susceptible to vancomycin, ampicillin, tetracycline, chloramphenicol, and aminoglycosides and does not have any hemolytic or gelatinase activity, or cytotoxic effect on Caco-2 cells. Altogether, these findings confirm the lack of hazardous traits in \textit{E. durans} OSY-EGY. Mining \textit{E. durans} OSY-EGY genome, for probiotic-related sequences, revealed genes associated with acid and bile salts tolerance, adhesion, competitiveness, antioxidant activity, antimicrobial activity, essential amino acids production, and vitamins biosynthesis. Phenotypically, \textit{E. durans} OSY-EGY was tolerant to acidic pH (3.0), and presence of 0.3% bile salts. The bacterium showed adhesion capability to Caco-2 cells, cholesterol-lowering effect, DPPH scavenging activity, and antimicrobial activity against several Gram-positive pathogenic bacteria. Based on the current work, we propose that \textit{E. durans} OSY-EGY is a potentially safe strain with desirable probiotic and antimicrobial traits. Thus, the investigated strain could be a promising candidate for several industrial applications.

Keywords: probiotics, \textit{Enterococcus durans}, genome mining, safety, bioinformatics

INTRODUCTION

Enterococci are non-spore forming bacteria with Gram-positive cell wall and fermentative metabolism (Ludwig et al., 2009). They are characterized by their tolerance to heat, salinity and extreme pH (Hanchi et al., 2018). Enterococci could be found in fermented food products such as cheeses, sausages, olives and vegetables (Franz et al., 1999; Giraffa, 2002). The occurrence of enterococci in food has been viewed for long time as an indicator
of poor manufacturing practice and product contamination (Thompson and Marth, 1986; Halkman and Halkman, 2014); however, other researchers consider enterococci to have a minimum role as a hygienic index in the food industry (Birolo et al., 2001). Presence of enterococci in raw-milk-cheeses at populations up to $10^8$ CFU/g suggests their commensal nature or their role as natural starter culture (Giraffa et al., 1997). These bacteria may have a role in ripening, aroma development and shelf-life improvement of fermented foods (Foulquie Moreno et al., 2006). Some strains produce enterocins, which are antimicrobial peptides active against some foodborne pathogens and spoilage bacteria (Khan et al., 2010).

Desirable probiotic characteristics have been reported in some enterococcal strains; these include their ability to inhabit human and animals gastrointestinal tract (GIT) and effectively participate in developing gut microbiome (Dominguez-Bello et al., 2010). Enterococcal strains also may exert their probiotic functions throughout immune system regulation, antioxidant activity, maintaining normal intestinal microflora, and lowering cholesterol levels (Franz et al., 2011). When ingested in high numbers, some enterococci may improve remission of irritable bowel syndrome or antibiotic-associated diarrhea (Gaggia et al., 2010; Kreuzer et al., 2012). Enterococcus faecalis and E. faecium were used as commercial probiotics or feed additives (Franz et al., 2011) whereas other species such as E. durans and E. hirae were proposed for such use (Nami et al., 2014, 2019; Pieniz et al., 2014). Examples of commercial enterococci probiotic preparations are E. faecium NCIMB 10415 (SF68), used in Cerinvet® (Cerbios-Pharma SA, Switzerland) and Cylacin® (Hoffmann-La Roche, Basel, Switzerland), and E. faecalis Symbioflor® 1 used in Symbioflor 1 (Symbiopharm, Herborn, Germany) (Serio et al., 2010; Baccouri et al., 2019).

Despite these beneficial uses, some enterococcal strains have been associated with human diseases and nosocomial infections. These strains can cause bacteremia, urinary tract infection, endocarditis, surgical site infection, and diarrhea (Murray and Weinstock, 1999; Kayser, 2003; Klare et al., 2003; Werner et al., 2011). Potentially pathogenic enterococci have been associated with hospital infections, but these are rarely associated with infections outside healthcare settings (Sanders et al., 2010). It has been proposed that the use of broad spectrum antibiotics, catheters, immune-suppressors or chemotherapy affects host-microbe balance and facilitates infection with some enterococci, mostly E. faecalis and E. faecium (Murray, 2000; Ubeda et al., 2010). Potentially pathogenic enterococci usually carry clinically relevant antibiotic resistances and marker virulence factors (Ike, 2017). Considering these findings, Enterococcus spp. are neither recommended for the “qualified presumption of safety” list of biological agents by the European Food Safety Authority (EFSA) nor have the generally recognized as safe (GRAS) status from the US Food and Drug Administration (Hanchi et al., 2018). For distinction between commensal/beneficial and potentially pathogenic enterococcal strains, comprehensive assessment of their safety characteristics is necessary (EFSA, 2012a,b).

The rise of antimicrobial resistance in foodborne pathogens and the need for natural food bio-preservatives prompted the search for new strains capable of producing potent antimicrobial agents. E. durans OSY-EGY, used in this study was isolated from artisanal cheese and showed a promising antimicrobial activity against selected pathogenic species (Hussein et al., 2019). The current study was initiated to thoroughly explore the safety, antimicrobial and probiotic traits of E. durans OSY-EGY and its potential usefulness to the industry.

**MATERIALS AND METHODS**

**Bacterial Strains and Culture Conditions**

E. durans OSY-EGY was streaked on de Man, Rogosa and Sharpe (MRS) agar (Oxoid, Thermo scientific, Waltham, MA, United States), and its overnight subculture in MRS broth was mixed with 80% sterile glycerol in a 1:1 ratio and stocked at −80°C. In preparation for experiments, frozen stock culture was streaked on MRS agar and inoculated plates were incubated at 30°C for 48 h followed by cultivation in MRS broth at 30°C for 18 h. E. faecalis Symbioflor 1 strain was isolated from Symbioflor® 1 commercial preparation (SymbioPharm, Herborn, Germany), by streaking on MRS agar and incubation at 30°C for 48 h followed by cultivation in MRS broth at 30°C for 18 h. The control strains, Bacillus cereus ATCC 14579, Escherichia coli K12, Staphylococcus aureus ATCC 25923, E. faecalis ATCC 29212 and E. coli BL21-pET22 (+) (Invitrogen, Carlsbad, CA, United States), Listeria monocytogenes Scott A, and S. aureus ATCC 29213 were obtained from the culture collection of the food microbiology laboratory, at the Ohio State University (Columbus, OH, United States).

**Genotypic Characterization**

**Screening E. durans OSY-EGY Genome for Safety- and Probiotic-Related Traits**

For safety assessment, E. durans OSY-EGY genome (Hussein et al., 2019) was screened using the Comprehensive Antibiotic Resistance Database (CARD) (Jia et al., 2017) and Virulence Factor of Bacterial Pathogens Database (VFDB)¹ (Chen et al., 2005). Additionally, E. durans OSY-EGY genome was mined for genes associated with biosynthetic pathways of biogenic amines using KAAS-KEGG Automatic Annotation Server² (Moriya et al., 2007) and KEGG Mapper³ (Kanehisa et al., 2019). The genome was also screened for the presence of Clustered Regularly Interspersed Short Palindromic Repeats (CRISPR) using CRISPR Finder⁴ (Grissa et al., 2007). For beneficial traits, E. durans OSY-EGY draft genome was mined for genes associated with biosynthetic pathways of essential amino acids and vitamins using KAAS-KEGG Automatic Annotation Server (see text footnote 2) (Moriya et al., 2007) and KEGG Mapper (see text footnote 3) (Kanehisa et al., 2019).

**Comparative Genomic Analysis**

For comparative genomic analysis, the genomic sequences of eleven strains were selected to represent either probiotic

1http://www.mgc.ac.cn/VFs/main.htm
2http://www.genomel.jp/kegg/kaas/
3https://www.genome.jp/kegg/mapper/
4http://crispr.i2bc.paris-saclay.fr/Server/
or potentially pathogenic enterococci. Group 1, representing probiotic enterococci, included four commercial probiotic strains (E. faecium T110, E. faecium L3, E. faecium LX, and E. faecalis Symbioflor 1) and two potential probiotic strains (E. durans KLD6.0930 and E. faecium 17OM39). Group 2, representing potentially pathogenic enterococci, included five strains (E. faecium DO, E. faecium 6E6, E. faecium Aus0085, E. faecium Aus0004, and E. faecium E39). The chromosomal genome sequences of these eleven strains were downloaded from the GenBank database using their GenBank accession numbers listed in Table 1. E. durans OSY-EGY draft genome was compared with these selected genomes based on the presence of antibiotic resistance, virulence genes, genes associated with acid tolerance (Ladero et al., 2013; Liu et al., 2016), bile salt tolerance (Budin-Verneuil et al., 2007; Hamon et al., 2011), cellular adhesion (Ladero et al., 2013; Hymes and Klaenhammer, 2016; Liu et al., 2016), competitiveness and persistence (Ghattargi et al., 2018), and antioxidant effects (Li et al., 2018a), retrieved from literature and analyzed using online NCBI BLAST tools; BLASTN for nucleotide sequences (Chen et al., 2013) or TBLASTN for amino acid sequences (Gertz et al., 2006). The presence and absence of genes, in the compared genomes, were visualized as heatmaps constructed using R.

To decipher the genomic difference between E. durans OSY-EGY and five genomes of the potentially pathogenic group, BLAST atlas was generated to align the query genomes using E. faecium DO as a reference. The BLAST atlas was drawn using BLAST Ring Image Generator (BRIG) (Alikhan et al., 2011).

Genomes of E. durans OSY-EGY and six potential or commercial probiotic enterococci were additionally compared. BLAST atlas was generated to align the query genomes using E. durans OSY-EGY as a reference. Sequences encoding bacteriocins were searched in the query genomes using the Bioinformatics and secondary metabolite analysis shell, antiSMASH v4.1.0 (Blin et al., 2018) and the web-based bacteriocin genome mining tool, BAGEL v4.0 (Walsh et al., 2011).

Detection of Selected Virulence Genes by Polymerase Chain Reaction (PCR)

PCR analysis was conducted on E. durans OSY-EGY and E. faecalis Symbioflor 1 to assess the presence of selected enterococcal virulence determinants and genes encoding biogenic amines. The analysis covered the following groups of genes; (i) genes associated with tissue damage that include cylA (cytolysin), gelE (gelatinase), and hyl (hyaluronidase); (ii) genes involved in adhesion and colonization, which include asa1 and agg (aggregation substances), esp (enterococcal surface protein), ace (collagen adhesion protein), and efaA (endocarditis antigen); and (iii) genes encoding biogenic amines, i.e., hdc (histidine decarboxylase), ldc (tyrosine decarboxylase) and odc (ornithine decarboxylase). For Genomic DNA (gDNA) extraction, E. durans OSY-EGY and E. faecalis Symbioflor 1 were grown in MRS broth at 37°C for 16 h. Aliquots (1 ml) of each culture were centrifuged at 10,000 × g for 10 min at 4°C (Model 5415R: Eppendorf, Hauppauge, NY, United States) and cell pellets were washed two times with sterile saline solution. The gDNA was isolated from the cell pellets using genomic DNA purification kit (Wizard® kit; Promega, Madison, WI, United States) following the manufacturer’s protocol. PCR amplification was performed in 30 µL reaction mixture containing 1 µg of gDNA, 1 × PCR buffer, 1.5 mM MgCl2, 0.2 mM of dNTP mix, forward primer, and reverse primer and 2 U Taq DNA polymerase (Platinum®; Thermo Fisher Scientific, Waltham, MA, United States). Genes, corresponding primers, primer concentration, product size and the PCR conditions applied are presented in Table 2. Amplifications were done by a thermal cycler (CFX96 Real-Time System; Bio-Rad, Hercules, CA, United States). Amplicon visualization was done with DNA

**TABLE 1 | Genomes of Enterococcus durans OSY-EGY and probiotic and potentially pathogenic members of the genus.**

| NCBI® strain identifiers | Source | GenBank accession | Genome size (Mb) | GC% | CDS | References |
|-------------------------|--------|-------------------|------------------|-----|-----|------------|
| E. durans OSY-EGY       | Artisanal cheese | GCA_004330425.1 | 3.2 | 37.69 | 3487 | Hussein et al., 2019 |
| **Potential probiotic**  |        |                   |                  |     |     |            |
| E. durans KLD6.0930     | Fermented cream | CP012384.1      | 2.8 | 38.0 | 2569 | Li et al., 2018a |
| E. faecium 17OM39       | Feces   | GCA_001652715.1  | 2.8 | 38.5 | 2639 | Ghattargi et al., 2018 |
| **Commercial probiotic**|        |                   |                  |     |     |            |
| E. faecium T110         | Commercial preparation | CP006030.1 | 2.7 | 38.4 | 2522 | Natarajan and Parani, 2015 |
| E. faecium L3           | Commercial preparation | GCA_000787055.1 | 2.6 | 38.0 | 2559 | Suvorov et al., 2019 |
| E. faecium LX           | Commercial preparation | GCA_000787068.1 | 2.7 | 38.3 | 2641 | Suvorov et al., 2019 |
| E. faecalis Symbioflor1 | Commercial preparation | GCA_000317915.1 | 2.8 | 37.7 | 2810 | Domann et al., 2007 |
| **Potentially pathogenic**|        |                   |                  |     |     |            |
| E. faecium DO           | Blood   | CP003583.1       | 2.6 | 37.9 | 2703 | Lam et al., 2012 |
| E. faecium 6E6          | Feces   | CP013994.1       | 2.9 | 37.6 | 3307 | Geldart and Kaznessis, 2017 |
| E. faecium Aus0085      | Blood   | CP006620.1       | 2.9 | 37.9 | 2938 | Zhong et al., 2017 |
| E. faecium Aus0004      |         | CP003351.1       | 2.9 | 38.3 | 2860 | Zhong et al., 2017 |
| E. faecium E39          | Blood   | CP011281.1       | 2.7 | 37.8 | 2907 | Geldart and Kaznessis, 2017 |

*National Center for Biotechnology Information.
was determined against *E. durans* erythromycin, gentamycin, streptomycin, and chloramphenicol (ampicillin, kanamycin, vancomycin, clindamycin, tetracycline, erythromycin, gentamycin, streptomycin, and chloramphenicol) (Eaton and Gasson, 2001).

The minimum inhibitory concentration (MIC) of 9 antibiotics was determined using a broth microdilution method (Wikler et al., 2006). Briefly, two-fold serially diluted antibiotics, at final concentrations of 1, 2, 4, 8, 16, 32, 64, 128, 256, 512, and 1,024 µg/ml, were prepared before 50-µl aliquots of the antibiotics’ preparations were added into 96-well plates (Corning, Tewksbury, MA, United States). This was followed by adding equal volume of *E. durans* OSY-EGY culture suspension that was adjusted to OD$_600$ of 0.001 in Muller Hinton broth (BD Diagnostic, Franklin Lakes, NJ, United States). The MIC of each antibiotic was determined as the lowest concentration at which no growth of the OSY-EGY strain was observed following incubation for 24 h at 37°C. Interpretations for susceptibility to each antibiotic was based on the guidelines adopted by EFSA (2012a). The test was performed in triplicate.

Gelatinase Activity
*E. durans* OSY-EGY was tested for gelatinase production using a method described previously (Su et al., 1991) with some modifications. Briefly, single colony of *E. durans* OSY-EGY was streaked on nutrient agar (BD Diagnostic) containing 3% gelatin (BD Diagnostic) and incubated at 37°C for 24 h. After incubation, saturated solution of ammonium sulfate (Fisher scientific, Pittsburgh, PA, United States) was poured on the surface of the medium to precipitate the non-hydrolyzed gelatin. Transparent haloes around the colonies were indicative of the gelatinase activity. *B. cereus* ATCC 14579 was used as a positive control and *E. coli* K12 was used as a negative control. The test was repeated three times and averages were reported.

Hemolysis Activity
Hemolysis activity (Eaton and Gasson, 2001) was tested after growing culture of *E. durans* OSY-EGY overnight at 37°C on tryptic soy agar supplemented with 5% sheep blood (Remel San Diego, CA, United States). *S. aureus* ATCC 25923 was used as positive control for β hemolysis and *E. faecalis* ATCC 29212 was used as negative control.
used as negative control. The test was repeated three times and averages were reported.

**Determination of Cytotoxicity**

Human colorectal adenocarcinoma cell line Caco-2 cells (HTB-37®, American Type Culture Collection, Manassas, VA, United States) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Thermo Fisher Scientific) containing 4.5 g/L glucose and supplemented with 15% heat-inactivated fetal bovine serum (FBS), 1% non-essential amino acids, 1% l-glutamine, and 1% penicillin-streptomycin (Gibco®). The cells were incubated at 37°C with 5% CO₂. Caco-2 cells were grown in T-75 flasks (Corning®, Corning, NY, United States) for 4–6 days until reaching 70–90% confluence, then dispersed using 0.05% trypsin-0.5 mM EDTA (Gibco, Thermo Fisher Scientific). Cells were sub-cultured in the appropriate plates depending on the experiment to be performed. After reaching 100% confluency, the cells were incubated at 37°C for 11–14 days, a period at which they become highly differentiated. The medium was refreshed every second day with fresh DMEM medium. At 100% confluency, the content of the FBS was decreased to 7.5% (v/v).

Caco-2 cells were seeded in 96-well culture plate (Corning®), at a density of 2 × 10⁴ cells/well and incubated as described earlier until post-confluence. DMEM medium was removed and Caco-2 cells were washed with calcium and magnesium-free Dulbecco’s phosphate buffered saline (DPBS) (Gibco, Thermo Fisher Scientific) followed by adding DMEM containing 1% (v/v) FBS.

*E. durans* OSY-EGY and *E. faecalis* Symbioflor 1 were cultured in MRS broth at 30°C for 18 h, the cultures were centrifuged at 16,000 × g for 2 min and the resulting cell pellets were washed two times in DPBS. Antibiotic-FBS-free DMEM was used to resuspend and dilute the cell pellets to final cell density of 10⁸ CFU/ml. Caco-2 cells were then exposed to *E. durans* OSY-EGY or *E. faecalis* Symbioflor 1 cells and the plate was incubated at 37°C for 24 h. After incubation, the cytotoxicity was evaluated by measuring the activity of lactate dehydrogenase (LDH) released in the culture media by the damaged cells using cytotoxicity detection kit (Roche, Basel, Switzerland) following manufacturer’s recommendations. The final absorbance was measured at 490 nm and 680 nm (test and reference wavelengths, respectively) using a microplate reader (Multiskan GO, Thermo Scientific). The results were expressed as percent of the positive control (Caco-2 cells exposed to 1% of Triton X-100). The Caco-2 cells was also observed using inverted microscope after 3 h of exposure to *E. durans* OSY-EGY or *E. faecalis* Symbioflor 1 cells suspended in DMEM to final cell density of 10⁶ CFU/ml, compared to untreated Caco-2 cells.

**Phenotypic Assessment of Probiotic Characteristics**

**Acid Tolerance**

The acid tolerance of *E. durans* OSY-EGY was tested as previously described (Ramos et al., 2013) with some modifications. *E. durans* OSY-EGY was cultured in MRS broth at 30°C for 18 h followed by centrifugation at 16,000 × g for 10 min at 4°C (Model 55415R; Eppendorf). The cell pellets were resuspended in a freshly pH-adjusted MRS. The MRS was adjusted to pH 2.0 and pH 3.0 using 1 N HCl (Fisher Scientific) to mimic the gastric acidic conditions and to pH 7.0 using 1N NaOH (Fisher Scientific) as control. The final cell density was adjusted to approximately 10⁸ CFU/ml. After incubation at 37°C for 2 h, 1-ml samples were taken immediately before and after the incubation, and tenfold serially diluted before spread-plating on MRS agar. After incubation at 30°C for 48 h, the colonies were counted and expressed as Log₁₀ CFU/ml. The assay was performed in duplicate and repeated three times.

**Bile Salts Tolerance**

For testing the bile tolerance, the previously described method (Walker and Gilliland, 1993) was followed with some modifications. Fresh 18 h culture of *E. durans* OSY-EGY was inoculated, at final cell density of 10⁸ CFU/ml, in MRS broth supplemented with 0.3% bile salts (Oxgall, Sigma-Aldrich). Cells grown in MRS broth without bile salt was used as control. Culture aliquots, 200 µl each, were distributed into 96-well microplate (Corning) before incubation at 37°C for 9 h in anaerobic jar to simulate human intestinal conditions. Bacterial growth was monitored by measuring the culture’s optical density at 600 nm (OD₆₀₀) hourly using microplate reader (UV max; Molecular Devices). The measured absorbance values were plotted against the time of incubation and compared with the control. The assays were performed in triplicate and repeated three times.

**Bacterial Adhesion to Caco-2 Cells**

Caco-2 cells were seeded in 12-well culture plate (Corning®), at a density of 1 × 10⁵ cells/well, and incubated as described earlier until post-confluence. DMEM medium was removed, and the monolayer of Caco-2 cells was washed two times with antibiotic-FBS-free DMEM. *E. durans* OSY-EGY or *E. faecalis* Symbioflor 1 were cultured in MRS broth at 30°C for 18 h, cultures were centrifugated at 16,000 × g for 2 min and the cell pellets were washed two times in DPBS. Antibiotic-FBS-free DMEM was used to resuspend and dilute the cell pellets to final cell density of 10⁶ CFU/ml. The Caco-2 cell were co-cultured with 1 mL of bacterial cell suspension and incubated 37°C for 3 h. The medium was aspirated to remove the non-adhering bacterial cells, and Caco-2 cells were rinsed three times with 1 mL of DPBS. The cell suspension including bacterial and Caco-2 cells were recovered from each well, centrifuged at 8,000 × g for 10 min at 4°C, and washed twice with 1 mL of DPBS. The bacterial cell suspension was incubated 37°C for 48 h. Bacterial cell adhesion was expressed as percent bacterial CFU attached to Caco-2 cells, relative to the initial bacterial population added per well. The results correspond to the means of two independent experiments, three replicates each.

**Auto-Aggregation**

Auto-aggregation test was performed as described previously (Del Re et al., 2000) with modifications. Overnight cultures of
**E. durans OSY-EGY and E. faecalis** symbioflor 1 were harvested and cell pellets were washed twice with sterile phosphate buffer saline (PBS, pH 7.0) and resuspended in the same buffer to obtain a cell suspension of approximately 10⁸ CFU/ml. Portions (4 ml each) of cell suspensions were incubated at 37°C for 24 h. One-milliliter aliquots of the supernatants at time 0 and 24 h of incubation without agitation were transferred to a spectrophotometer cuvette and absorbance (OD₆₀₀) at these two points (A₀ and A₂₄h, respectively) was measured. The percentage of auto-aggregation was then calculated as follows:

\[
\text{Auto\_aggregation (\%)} = \left(1 - \frac{A_{24h}}{A_0}\right) \times 100
\]

The assay was performed in triplicate.

**Hydrophobicity**

Hydrophobicity test was performed as initially described (Rosenberg et al., 1980) with some modifications. Overnight cultures of *E. durans* OSY-EGY and *E. faecalis* symbioflor 1 were harvested and cell pellets were washed twice with sterile phosphate buffer saline (PBS, pH 7.0) and resuspended in the same buffer to obtain a cell suspension of approximately 10⁸ CFU/ml. One-milliliter of toluene (99.8%; Sigma-Aldrich) was added to 3 ml of each cell suspension, vortexed for 90 s and incubated at 37°C for 1 h for phase separation. After incubation, OD₆₀₀ nm of aqueous phase was measured and hydrophobicity was calculated as follows:

\[
\text{Hydrophobicity (\%)} = \left(1 - \frac{A}{A_0}\right) \times 100
\]

where A₀ and A are the measured absorbance values before and after mixing with toluene, respectively. The assay was performed in triplicate.

**Antioxidant Effect**

The radical scavenging ability of 2,2-diphenyl-1-picrylhydrazyl (DPPH) was used to evaluate the antioxidant effect (Kedare and Singh, 2011). The assay was performed on *E. durans* OSY-EGY as described previously (Brand-Williams et al., 1995) with some modifications. The DPPH was freshly prepared in methyl alcohol as a blank. Aliquots (100 µl) of filter-sterilized cell-free supernatant of *E. durans* OSY-EGY strain were mixed with 3.9 ml of DPPH radical solution. Methyl alcohol was used as a blank. Aliquots (100 µl) of water mixed with 3.9 ml of DPPH solution were prepared as control. The absorbance of the resulting solutions was measured at 515 nm at 5-min intervals for 65 min. The assay was performed in triplicate.

\[
\text{Cholesterol removal (\%)} = \left(1 - \frac{A_s}{A_c}\right) \times 100
\]

where A₀ and A are the absorbance at 550 nm for *E. durans* OSY-EGY supernatant and control (un-inoculated Cholesterol-MRS broth), respectively.

**Antimicrobial Activity Assessment**

The antimicrobial potential of *E. durans* OSY-EGY was assayed using the previously described spot-on-lawn method (He et al., 2007). Briefly, stock culture of *E. durans* OSY-EGY was streaked on MRS agar followed by incubation at 30°C for 48 h. Subsequently, a single colony was inoculated in MRS broth followed by incubation at 30°C for 48 h. The obtained fermentate was centrifuged at 7,710 × g for 15 min and the culture supernatant was filter-sterilized using 0.45-μm syringe filter (Millex HV Durapore PVDF; Merk Millipore, Ltd., Cork, IRL). The resulting cell-free supernatant (CFS) was assayed for antimicrobial efficacy against selected bacterial strains (Table 3) as follows. Aliquots (10 µl) of overnight cultures of tested bacteria were transferred into 10 ml sterile molten TSA soft agar (0.75% agar). The inoculated soft agar was overlayed onto basal TSA agar plates. After the soft agar solidified, 10 µl of the CFS were spotted on the indicator lawn. After overnight incubation at 37°C, the clear inhibitory areas, where the CFS was spotted, were observed.

**Statistical Analysis**

Statistical analysis was performed using R (see text footnote 5). Data were expressed as mean ± standard deviation (SD). Statistical significance was determined using one-way analysis of
TABLE 3 | Antimicrobial activity of Enterococcus durans OSY-EGY against selected bacteria.

| Tested bacteria | Activity |
|-----------------|----------|
| Gram-positive   |          |
| 1 Bacillus cereus ATCC 14579 | +\textsuperscript{2} |
| *Enterococcus faecalis ATCC 29212 | + |
| Listeria monocytogenes Scott A | + |
| 1 Staphylococcus aureus ATCC 29213 | + |
| Gram-negative   |          |
| 1 Escherichia coli K12 | – |

\textsuperscript{2} Antimicrobial activity was observed as visible inhibition of growth during bioassay, as described in the materials and methods section.

variance (ANOVA) for comparisons among treatments. Control-treatment comparisons were performed by Student’s t-test and significance was considered at $p < 0.05$.

RESULTS

A new lactic acid bacterium strain, *E. durans* OSY-EGY, was isolated from an artisanal cheese and found to have a promising antimicrobial activity that could be beneficial in food applications (Hussein et al., 2019). Before proposing the use of the strain in further industrial applications, research is needed to assess its safety, antimicrobial, and probiotic traits. This study, therefore, was initiated to thoroughly assess these traits using genomic and phenotypic analyses.

Safety and Probiotic-Related Traits in *E. durans* OSY-EGY Genome

The draft genome of *E. durans* OSY-EGY was mined for genetic determinants associated with safety and probiotic traits. The strain was found lacking genes encoding hyaluronidase (*hyl*), cytolsin (*cyIA*), gelatinase (*gelE*) and genes involved in biogenic amines biosynthesis except tyramine decarboxylase (*tdc*) for tyramine production. For immunity against mobile genetic elements, *E. durans* OSY-EGY genome was found to contain one confirmed and four potential CRISPR arrays. The genome, however, was found to contain genes involved in biosynthesis of the essential amino acids tryptophan, phenylalanine, methionine, valine, leucine, isoleucine, histidine, arginine and lysine (Table 4) and the vitamins pantothenate, thiamin, riboflavin and folate (Table 5).

Comparative Genomic Analysis

Genomic comparison was performed to reveal the differences between this strain or probiotic or pathogenic enterococci. When screened for the presence of antibiotic resistance genes (Figure 1A), *E. durans* OSY-EGY and *E. durans* KLD56.0930 genomes were found to contain *aac(6)-Iid* and LIU_RS08465 genes, which are associated with aminoglycosides and tetracycline resistance, respectively. The genome of the commercial probiotic T110 possessed genes involved in vancomycin, aminoglycosides and macrolides resistance. Genomes of the potentially pathogenic strains (DO, Aus0085, or 6E6) harbored genes conferring resistance to vancomycin, tetracycline, aminoglycosides, and macrolides. When screening for the presence of virulence genes (Figure 1B), *E. durans* OSY-EGY genome was void of the virulence factors *IS16, acm, Scm, SgrA* and *esp*. However, genes associated with adhesion (*ebpA, ebpB, ebpC, srtC, EfaA* and *sagA*), pili formation (*pilA, pilB, pilE* and *pilF*) and biofilm formation (*hopD*) existed in all enterococcal genomes.

The ability of probiotics to exert health benefits depends on their survival and persistence in the GIT. Genes encoding these traits such as acid and bile tolerance, competitiveness, persistence, and adherence were mined in the compared genomes. All studied genomes encoded acid tolerance, bile tolerance, competitiveness, and persistence genes (Figure 2A). Genes encoding cell adhesion-associated proteins existed in all
TABLE 5 | Vitamins biosynthetic proteins detected in *Enterococcus durans* OSY-EGY genome.

| Vitamins | Biosynthesis protein |
|----------|----------------------|
| Thiamine | Thiamine phosphate phosphatase |
|          | 5-amino-6-(5-phospho-D-ribitylamino) uracil phosphatase |
| Riboflavin | Dihydrofolate reductase |
|          | Folate-folate synthase |
|          | Dihydroneopterin aldolase |
| Folate   | Type I pantothenate kinase |
|          | Phosphopantothenoyl cysteine decarboxylase |
|          | Phosphopantothenoyl cysteine — cysteine ligase |

Genomes except those encoding S-layer protein and collagen binding proteins, which were found only in *E. durans* OSY-EGY and probiotic genomes. The strains OSY-EGY, KLDS6.0930, and T110 contained several genes involved in the biosynthesis of exopolysaccharides. The shortage of these genes in the potentially pathogenic strains may indicate the competitive advantage of the probiotic strains to colonize the GIT (Figure 2B). The *E. durans* OSY-EGY and KLDS6.0930 were found to share 14 genes associated with antioxidant activities, suggesting their potential ability to survive in the host environment. In comparison, only six genes associated with antioxidant activity were found in the potentially pathogenic genomes (Figure 2C). Detailed information about all genes used for comparison is listed in the Supplementary Tables 1–5. Genome of *E. durans* OSY-EGY was aligned with those of potentially pathogenic enterococci and results are shown in Figure 3A. This genomic comparison revealed how different and distantly removed is *E. durans* OSY-EGY from the potentially pathogenic strains. When aligning genomes of *E. durans* OSY-EGY with probiotic enterococci, it was found that *durans* KLDS6.0930, a well characterized potential probiotic (Li et al., 2018b), has the highest similarity to *E. durans* OSY-EGY. Compared to other genomes, *E. durans* OSY-EGY has the advantage of carrying genes encoding multiple bacteriocins; these are two novel sequences of lantibiotics A and B, enterocin N, and the two previously known enterocins, L50A and L50B (Figure 3B).

**Detection of Virulence Genes and Screening for Plasmids**

For confirming the *in silico* analysis of selected virulence factors and biogenic amines production, PCR was conducted on the genomic DNA extracted from OSY-EGY and Symbioflor 1, using primers specific for the corresponding genes (Table 2). The results showed that *GelE*, *cylA*, *asa1*, *esp*, *hdc*, *odc* were absent in *E. durans* OSY-EGY and Symbioflor 1 genomes. *Ace*, *agg* and *hyl* genes were found only in Symbioflor 1 genome. The genes *EfaA* and *tdc* were found in the genomes of both *E. durans* OSY-EGY and Symbioflor 1 (Table 6), which confirmed the genomic analysis findings.

Plasmids include considerable portion of genomic information associated with antibiotic resistance and virulence factors. Plasmid DNA was extracted from *E. durans* OSY-EGY, Symbioflor 1 and *E. coli* Pet22b strains followed by...
visualization using gel electrophoresis. Unlike *E. coli* Pet22b, *E. durans* OSY-EGY and Symbioflor 1 were devoid of plasmids (Data are not shown).

### Phenotypic Assessment of Safety-Related Traits

The minimum inhibitory concentrations (MICs) for nine antibiotics were determined against *E. durans* OSY-EGY (Table 7). Results show that the strain is susceptible to all tested antibiotics. The absence of cytolysin and gelatinase genes, revealed from the genomic analysis, was confirmed using the phenotypic assays. Unlike *B. cereus* ATCC 14579, *E. durans* OSY-EGY did not exhibit any gelatin hydrolysis (Figure 4A). When *E. durans* OSY-EGY was grown on blood agar, it did not exhibit any hemolytic effects, compared to *S. aureus* ATCC 25923 which produced strong β hemolysis (Figure 4A).

After 24 h of treating Caco-2 cells with *E. durans* OSY-EGY or *E. faecalis* Symbioflor 1, the amount of LDH released was measured as an indicator of cytotoxic effect. The results showed that there was no significant difference (*p > 0.05*), in the LDH release (approximately 5%), between *E. durans* OSY-EGY, *E. faecalis* Symbioflor 1, or PBS-treated cells (Figure 4B). The microscopic observation did not show differences in the morphology of treated or untreated Caco-2 cells (Figure 4C).

### Phenotypic Assessment of Probiotic-Related Traits

When *E. durans* OSY-EGY was exposed to pH 3.0 for 2 h at 37°C, the strain population did not decrease significantly (*P > 0.05*) as shown in Figure 5A. However, there was a decrease in the population (*P < 0.05*) after holding *E. durans* OSY-EGY at pH 2.0 for 2 h. These results indicate that *E. durans* OSY-EGY can survive acidic conditions as low as pH 3.0. The strain OSY-EGY...
also grew uninhibited for 8 h in the presence of bile salt at a concentration of 0.3% (p > 0.05), as shown in Figure 5B.

OSY-EGY and Symbioflor 1 strains showed similar capabilities to adhere effectively to Caco-2 cells (Figure 6A). For additional adhesion characteristics, OSY-EGY and Symbioflor 1 were evaluated for auto-aggregation capabilities and hydrophobicity. The auto-aggregation capability was not significantly higher in OSY-EGY than in Symbioflor 1 strain (p > 0.05) (Figure 6B). Likewise, after 1 h of incubation with toluene, OSY-EGY strain showed non-significant increase in hydrophobicity than did Symbioflor 1 strain (Figure 6C).

When evaluating the antioxidant activity, E. durans OSY-EGY showed DPPH radicals scavenging ability of 9% after 65 min of incubation, compared to the initial DPPH concentration (Figure 7A). The strain also had a significantly higher cholesterol lowering potential (p < 0.05), compared to the uninoculated control medium (Figure 7B). The CFS of E. durans OSY-EGY showed antimicrobial activity when tested against selected bacterial stains (Table 3); these include the pathogenic B. cereus, L. monocytogenes, and S. aureus and the spoilage E. faecalis. However, E. durans OSY-EGY was not effective against the Gram-negative E. coli K12.
**TABLE 6** Detection of selected virulence and biogenic amines production genes in the genomes of *Enterococcus durans* OSY-EGY and *E. faecalis* Symbioflor 1.

| Gene | *E. durans* OSY-EGY | *E. faecalis* Symbioflor 1 |
|------|---------------------|---------------------------|
| efaA | D<sup>a</sup>       | D                         |
| ace  | ND<sup>b</sup>      | D                         |
| agg  | ND                  | D                         |
| asa1 | ND                  | ND                        |
| esp  | ND                  | ND                        |
| gelE | ND                  | ND                        |
| cyA  | ND                  | ND                        |
| hyf  | ND                  | D                         |
| odc  | ND                  | ND                        |
| ltc  | D                   | D                         |
| hdc  | ND                  | ND                        |

<sup>a</sup>Gene description is found in Table 2. <sup>b</sup>Detected. <sup>c</sup>Not detected.

**TABLE 7** The minimum inhibitory concentrations of selected antibiotics tested against *Enterococcus durans* OSY-EGY.

| Antibiotic | MIC   | Cut-off value* |
|------------|-------|----------------|
| Ampicillin | 2     | 2              |
| Clindamycin| 2     | 4              |
| Erythromycin| ≤1    | 4              |
| Kanamycin  | 512   | 1,024          |
| Streptomycin| 32    | 128            |
| Tetracycline| 4     | 4              |
| Vancomycin | 4     | 4              |
| Gentamycin | 32    | 32             |
| Chloramphenicol| 8    | 16             |

<sup>*The cut-off values are based on the guidelines of European Food Safety Authority (EFSA, 2012a) for the assessment of bacterial resistance to antibiotics.</sup>

**DISCUSSION**

*Enterococcus* spp. are known for their diversity, ubiquitous distribution in the environment, and presence in fermented foods (Ghattargi et al., 2018). There has been an extensive research interest in enterococci as probiotic candidates (Foulquié Moreno et al., 2006; Franz et al., 2011; Nami et al., 2014; Li et al., 2018b; Baccouri et al., 2019). To assess the safety and the industrial application feasibility of a strain, it is important to conduct genomic and phenotypic analyses on traits of interest. Emerging technologies such multi-locus sequence typing (Homan et al., 2002; Leavis et al., 2006; Ruiz-Garbajosa et al., 2006) and whole-genome sequence analyses (van Schaik et al., 2010; Qin et al., 2012; Beukers et al., 2017) have provided evidences that commensal enterococcal strains are different from the nosocomial infectious strains. Some of the genomic variability in *Enterococcus* spp. is due to the horizontal gene transfer leading to acquisition of mobile and foreign genetic elements such as bacteriophages and insertion sequence (IS) elements (Paulsen et al., 2003; Foulquié Moreno et al., 2006). Considering the potential hazards associated with gene transfer, new *Enterococcus* strains should be selected for industrial applications based on their genomes characterizations and absence of antibiotic resistance or virulence genes (Domann et al., 2007). A case-by-case safety evaluation assessment is critical to determine strain suitability for use as bio-protective culture or in probiotic preparations (Araújo and Ferreira, 2013; Hanchi et al., 2018).

In the current study, we found that *E. durans* OSY-EGY has a potent antimicrobial activity against Gram-positive, but not Gram-negative, bacteria. The strain was effective against *L. monocytogenes*, *S. aureus*, *E. faecalis*, and *B. cereus* and its genome was found to contain multiple bacteriocin biosynthetic gene clusters. Considering its promising antimicrobial activity, *E. durans* OSY-EGY has a potential to be used as bio-protective culture in some food fermentations. The presence of desirable probiotic characteristics is an additional advantage that may help in qualifying the strain for industrial applications. In terms of fitness and efficacy as a probiotic, antimicrobial activity is traditionally considered an important trait. Some researchers suggested that production of antimicrobials helps probiotic strains in competing against GIT microbes including pathogens (Gillor et al., 2009; Bosák et al., 2018).

In the current study, a genome analysis was conducted to assess the safety and probiotic traits in *E. durans* OSY-EGY, in comparison with known probiotic and potentially pathogenic *Enterococcus* strains (Ghattargi et al., 2018). BLAST Atlas revealed that *E. durans* OSY-EGY is closely related to the potential probiotic strain, KLDS6.0930, and distantly related to the potentially pathogenic group.

The antibiotic resistance is not uncommon in lactic acid bacteria (LAB), including strains proposed as probiotic candidates (Birri et al., 2012; Jeronymo-Ceneviva et al., 2014; Casarotti et al., 2017). In the GIT, there is a high potential for horizontal transfer of acquired antibiotic resistance genes among intestinal microbiota, including human pathogens. However, the horizontal transfer of intrinsic antibiotic resistance genes has a minimum potential (Devirgiliis et al., 2011; van Reenen and Dicks, 2011). EFSA requires the absence of acquired antibiotic resistance genes in bacterial strains, intended to be used in animal feed, as a critical part of its safety qualification (EFSA, 2012a). In *silico* analysis showed that *E. durans* OSY-EGY genome encodes genes that could be associated only with tetracycline (LIU_RS08465) and aminoglycoside (*aac(6′)-Iid*) resistance. In the current study, we screened, in *silico*, twenty *E. durans* genomes found in NCBI database for the presence of LIU_RS08465 and *aac(6′)-Iid* genes in an attempt to determine if these genes are associated with acquired antibiotic resistance. The results showed that these two genes were detected in all analyzed genomes (*Supplementary Table 6*) which indicates these antibiotic resistance genes are conserved in the genomes of *E. durans* and are associated with intrinsic resistances, with a low risk for lateral transfer (EFSA, 2012a). Additionally, we investigated the stability of *E. durans* OSY-EGY genome by analyzing for the presence of plasmids and CRISPER systems. *E. durans* OSY-EGY was found to be devoid of plasmids and its genome carries one confirmed and three potential CRISPR arrays which confers a sequence-based immunity and genome stability against phage modification and horizontal genes transfer (Marraffini and Sontheimer, 2008). Importantly, the antibiotic susceptibility test revealed that *E. durans* OSY-EGY is
susceptible to clinically relevant antibiotics including ampicillin, vancomycin, tetracycline, and aminoglycosides. Although the commercial probiotic, *E. faecalis* Symbioflor 1, was used for more than 50 years without reporting of any adverse effect (Domann et al., 2007), it was previously reported to be gentamycin and erythromycin resistant (Baccouri et al., 2019).

According to EFSA guidelines, when the strain is ampicillin sensitive and the virulence genes IS16, *esp* and *hyl* are absent, the strain is considered safe to be used as feed additive (EFSA, 2012b); *E. durans* OSY-EGY genome lacks these markers. Absence of selected virulence genes in *E. durans* OSY-EGY genome was also verified using PCR. However, the commercial probiotic strain Symbioflor 1 contains the virulence genes, *ace* and *hyl*, in its genome. These findings support that *E. durans* OSY-EGY does not carry any potential pathogenicity. On the other hand, genes associated with adhesion, pili formation and biofilm formation existed in all enterococcal genomes used for comparison (Figure 1B). The term virulence factor not only refers to elements that confer bacterial pathogenicity and development of infection but also to elements associated with cell adhesion and protection against host defense (Li et al., 2018b). However, factors involved in host cells adhesion and colonization of the intestine are needed in probiotics (Pillar and Gilmore, 2004; Wassenaar et al., 2015; Li et al., 2018b). The European Union recommended that the presence of confirmed known virulence genes in *Enterococcus* or other LAB strains should exclude these strains from use.

Before selecting new beneficial *Enterococcus* strain, its hemolytic activity and cytotoxic effect should be evaluated (Salminen et al., 1998). According to current study, *E. durans* OSY-EGY does not produce gelatinase or hemolysin. LDH assays are widely used for assessing the cytotoxic effect of proposed probiotic strains (Sanders et al., 2010; Hanchi et al., 2018). Using Caco-2 cells, coupled with LDH assay, to assess the cytotoxic effect of *E. durans* OSY-EGY and *E. faecalis* Symbioflor 1 showed that both strains had no cytotoxicity to this intestinal cell line. Members of LAB can synthesize biogenic amines from their precursor amino acids by amino acid decarboxylases (Benkerroum, 2016). Biogenic amines, including histamine, tyramine, ornithine, phenylethylamine and cadaverine, may cause intoxication if consumed in amounts that exceed critical thresholds (EFSA, 2011).
OSY-EGY and *E. faecalis* Symbioflor 1 were screened for the presence of genes associated with biogenic amines production, both strains were void of all investigated genes except that encoding tyrosine decarboxylase, which is involved in tyramine production. Compared to *E. durans* KLDS6.0930, as the closest strain to OSY-EGY, KLDS6.0930 genome was found to contain the genes for tyramine production. However, KLDS6.0930 strain produced tyramine in amount less than the critical threshold level (Li et al., 2018b). Additionally, presence of the gene does not necessarily mean the protein is expressed; hence, further phenotypic validation of tyramine production needs to be conducted in a further study.

According to the World Health Organization (WHO), probiotics are ‘live microorganisms which when administered in adequate amounts confer a health benefit on the host’ (Food and Agriculture Organization [FAO], and World Health Organization [WHO], 2001). In order to confer such benefits, the probiotic strain should have the capacity to persist and survive under GIT conditions. The strain tolerance to acidic environment and bile salts are two criteria for a candidate probiotic strain to survive the GIT (Nami et al., 2019). In our study, we performed genomic and phenotypic analyses to confirm such traits in *E. durans* OSY-EGY. Genomically, *E. durans* OSY-EGY and the potential probiotic strain, KLDS6.0930, contained genes that encode proteins associated with counteracting acid stress such as tyrosine-tRNA ligase (Ladero et al., 2013), ATPase V, Na+/H+ antiporter, H+/K+ uptake transporter (Liu et al., 2016) and Tyrosyl-tRNA synthetase. The expression of the latter increases under low pH, suggesting its potential role in acid stress response (Linares et al., 2012). All *Enterococcus* genomes tested contain genes associated with bile tolerance, namely, genes encoding choloylglycine hydrolase and cyclopropene-fatty-acyl-phospholipid synthase. Transcription of the latter increased in lactic acid bacteria in response to bile (Budin-Verneuil et al., 2007; Hamon et al., 2011). On the other hand, *E. durans* OSY-EGY showed acid tolerance when grown at pH 2 or 3 and did not encounter growth reduction in the presence of 0.3% bile salts. This augments the potential capability of the strain to survive similar harsh conditions found in the GIT.

Colonization in the GIT is a critical trait to be considered for a potential probiotic strain. All genomes studied in this work were found to encode for cell adhesion factors such as fibronectin-binding protein (Hymes and Klaenhammer, 2016), aggregation-promoting factor that could be contributing to gut milieu binding (Ladero et al., 2013), collagen-binding protein and proteins associated with extracellular polymeric substance production which enhance adhesion and persistence in the gut environment (Liu et al., 2016). Phenotypically, *E. durans* OSY-EGY showed adhesion capabilities to Caco-2 cells. Cell surface hydrophobicity is an additional characteristic associated with the adhesion capability of the probiotic strains. The higher ability of probiotics to adhere to epithelial cells is a result of higher cell surface hydrophobicity (Xu et al., 2009). In the current study, *E. durans* OSY-EGY and *E. Faecalis* (Symbioflor 1) showed worthy hydrophobicity characteristics (Figure 6C). The auto-aggregation is defined as same-species bacterial accumulation and the trait is important in aiding cellular adhesion (Collado et al., 2008; Campana et al., 2017). In current study, *E. durans* OSY-EGY and *E. Faecalis* Symbioflor 1 showed promising auto-aggregation abilities (Figure 6B). Altogether, these results suggest that *E. durans* OSY-EGY most probably would survive GIT harsh conditions.

Probiotic desirable traits may include production of antioxidants, vitamins, and essential amino acids, and expression of enteric pathogens antagonism. *E. durans* OSY-EGY and other six genomes were screened for genes known to be associated with antioxidant effect. *E. durans* OSY-EGY and KLDS6.0930 shared 14 genes coding for antioxidant traits and only 5 genes were found in the potentially pathogenic strains. Genomes of pathogenic strains may include genes associated with GIT survival and even some beneficial characteristics. However, the presence of known virulence factors and antibiotic resistance is what makes these strains pathogenic to the host (Ghattargi et al., 2018). Consistent with its antioxidant characteristic, *E. durans* OSY-EGY showed DPPH radical scavenging effect (9%). Compared to *E. durans* OSY-EGY, *E. durans* F3 showed better DPPH scavenging activity (more than 40%) (Alshammari et al., 2019). This could be attributed to strain-specific differences in their antioxidant activities or the types of the antioxidants produced (Wang et al., 2017). *E. durans* OSY-EGY genome was found to have genes involved in biosynthetic pathways of essential amino acids and vitamins. The synthesis pathways for vitamins and amino acid were reported previously to be absent in the genomes of the potentially pathogenic strains DO, Aus0085, and 6E6 of *E. faecium* (Ghattargi et al., 2018). Other health-promoting benefit such as cholesterol lowering effect was observed in *E. durans* OSY-EGY (Figure 7B). Removal of cholesterol and biosynthesis of vitamins and essential amino acids further support the potential applications of *E. durans* OSY-EGY in promoting health and possibly in developing nutrient-rich foods. The promising antimicrobial activity of *E. durans* OSY-EGY against Gram-positive pathogenic and spoilage bacteria, indicates its usefulness for several industrial applications.

**CONCLUSION**

Considering the antimicrobial effect of *E. durans* OSY-EGY, it was important to investigate its safety and to ensure its suitability for use in the industry as bio-protective or probiotic culture. The *in silico* comparative genomic analysis determined how distant is *E. durans* OSY-EGY from potentially pathogenic strains, as evident by the absence of antibiotic resistance and virulence genes. The analysis revealed genes associated with desirable probiotic traits such as acid tolerance, bile tolerance, competitiveness, persistence, adherence and health promoting effect. The functionality of the predicted genomic features was validated using a battery of *in vitro* analyses. From the findings of the current study, it can be concluded that *E. durans* OSY-EGY is potentially safe and beneficial strain that possesses desirable probiotic traits, in addition to its promising
antimicrobial activity. This support the notion that the strain is potentially suitable for use in various applications.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

AUTHOR CONTRIBUTIONS

WH analyzed the strain phenotypically and genetically, and drafted the manuscript. AA helped with the genomic and bioinformatic analyses and contributed to the phenotypic and antibiotic susceptibility testing, and writing and revising the manuscript. DR-M carried out the experiments on cell-line. IG-C helped with the tissue culture work and completed the plasmid isolation experiment. AY oversaw the project and reviewed and revised the manuscript. All authors read and approved the manuscript.

REFERENCES

Alikhan, N. F., Petty, N. K., Ben Zakour, N. L., and Beatson, S. A. (2011). BLAST ring image generator (BRIG): simple prokaryote genome comparisons. BMC Genom. 12:402. doi: 10.1186/1471-2164-12-402

Alshammari, E., Patel, M., Sachidanandan, M., Kumar, P., and Adnan, M. (2019). Enterococci. Biorollo, G. A., Reinheimer, J. A., and Vinderola, C. G. (2001).

Aly, A. H., Ismail, M. K., and Palenzona, D. (2017). Comparative genomic analysis for the presence of potential Enterococcal virulence factors in the probiotic strain Symbioflor 1. Int. J. Med. Microbiol. 297, 533–539. doi: 10.1016/j.ijmm.2007.02.008

Bosák, J., Micenková, L., Hrala, M., Pomorská, K., Kunova Bosakova, M., Krejci, P., et al. (2018). Colicin FY inhibits pathogenic Versinia enterococcales in mice. Sci. Rep. 8:12242. doi: 10.1038/s41598-018-30729-7

Brand-Williams, W., Cuvelier, M. E., and Berset, C. (1995). Use of a free radical method to evaluate antioxidant activity. LWT Food Sci. Technol. 28, 25–30. doi: 10.1016/S0022-6438(95)80008-5

Budin-Verneuil, A., Pichereau, V., Auffray, Y., Ehrlich, D., and Maguin, E. (2007). Proteome phenotyping of acid stress-resistant mutants of Lactococcus lactis MG1363. Proteomics 7, 2038–2046. doi: 10.1002/pmic.200600773

Campana, R., van Hemert, S., and Bafbone, W. (2017). Strain-specific probiotic properties of lactic acid bacteria and their interference with human intestinal pathogens invasion. Gut Pathog. 9:12. doi: 10.1186/s13099-017-0162-4

Casarotti, S. N., Carneiro, B. M., Todorov, S. D., Nero, L. A., Rahal, P., and Penna, A. L. B. (2017). In vitro assessment of safety and probiotic potential characteristics of Lactobacillus strains isolated from water buffalo mozzarella cheese. Ann. Microbiol. 67, 289–301. doi: 10.1007/s13213-017-1258-2

Chen, L., Yang, J., Yu, J., Yao, Z., Sun, L., Shen, Y., et al. (2005). VFDβ: a reference database for bacterial virulence factors. Nucleic Acids Res. 33, D325–D328. doi: 10.1093/nar/gki008

Chen, Y., Schmidt, B., and Maskell, D. L. (2013). Reconfigurable accelerator for the word-matching stage of BLASTN. IEEE Trans. Very Large Scale Integr. Syst. 21, 659–669. doi: 10.1109/TVLSI.2012.2196060

Choi, E. A., and Chang, H. C. (2015). Cholesterol-lowering effects of a putative probiotic strain Lactobacillus plantarum EM isolated from kimchi. IWT Food Sci. Technol. 62, 210–217. doi: 10.1016/j.iwt.2015.01.019

Collado, M. C., Meriluoto, J., and Salminen, S. (2008). Adhesion and aggregation properties of probiotic and pathogenic strains. Eur. Food Res. Technol. 226, 1065–1073. doi: 10.1007/s00226-007-0632-x

Del Re, B., Sgorbati, B., Miglioli, M., and Palenzona, D. (2000). Adhesion, autoaggregation and hydrophobicity of 13 strains of Bifidoebacterium longum. Lett. Appl. Microbiol. 31, 438–442. doi: 10.1046/j.1365-2672.2000.00845.x

Devirgiliis, C., Barile, S., and Perozzi, G. (2011). Antibiotic resistance determinants in the interplay between food and gut microbiota. Genes Nutr. 6, 275–284. doi: 10.1007/s12263-011-0226-x

Domann, E., Hain, T., Ghi, R., Billon, A., Kuenne, C., Zimmermann, K., et al. (2007). Comparative genomic analysis for the presence of potential Enterococcal virulence factors in the probiotic Enterococcus faecalis strain Symbioflor 1. Int. J. Med. Microbiol. 297, 533–539. doi: 10.1016/j.ijmm.2007.02.008

Domínguez-Bello, M. G., Costello, E. K., Vanderlact, M., Magris, M., Hidalgo, G., Fierer, N., et al. (2010). Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc. Natl. Acad. Sci. U.S.A. 107, 11971–11975. doi: 10.1073/pnas.1002601107

Eaton, T. J., and Gasson, M. J. (2001). Molecular screening of Enterococcus virulence determinants and potential for genetic exchange between food and medical isolates. Appl. Environ. Microbiol. 67, 1628–1635. doi: 10.1128/AEM.67.4.1628-1635.2001
EFSA (2011). EFSA panel on biological hazards (BIOHAZ). Scientific opinion on risk based control of biogenic amine formation in fermented foods. EFSA J. 9:2393. doi: 10.2903/j.efsa.2011.2393

EFSA (2012a). EFSA panel on additives and products or substances used in animal feed (FEEDAP). Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance. EFSA J. 10, 2740–2749. doi: 10.2903/j.efsa.2012.2740

EFSA (2012b). EFSA panel on additives and products or substances used in animal feed (FEEDAP). Guidance on the safety assessment of Enterococcus faecium in animal. EFSA J. 10:2682. doi: 10.2903/j.efsa.2012.2682

Food and Agriculture Organization [FAO], and World Health Organization [WHO] (2001). Probiotics in food: health and nutritional properties and guidelines for evaluation. Food Nutr. Pap. 85:71.

Foulquié Moreno, V. C., Gaikwad, M. A., Meti, B. S., Nimonkar, Y. S., Dixit, K., Prakash, O., et al. (2010). Probiotics and prebiotics in animal. EFSA (2012a). EFSA panel on additives and products or substances used in animal feed (FEEDAP). Guidance for the identification of key proteins in bile tolerance. Front. Microbiol. 8:e0303-19.

Hymes, J. P., and Klaenhammer, T. R. (2016). Stuck in the middle: fibronectin-binding proteins in Gram-positive bacteria. Front. Microbiol. 7:1504. doi: 10.3389/fmicb.2016.01504

Ike, Y. (2017). Pathogenicity of Enterococci. Nippon Saikagaku Zasshi 72, 189–211. doi: 10.3412/jsb.72.189

Jeronimo-Cenovica, A. B., de Paula, A. T., Silva, L. F., Todorov, S. D., Franco, B. D. G. M., and Penna, A. L. B. (2014). Probiotic properties of lactic acid bacteria isolated from water-buffalo mozzarella cheese. Probiot. Antimicrob. Proteins 6, 141–156. doi: 10.1128/s12602-014-9166-2

Jia, B., Raphenya, A. R., Alcock, B., Waglechner, N., Guo, P., Tsang, K. K., et al. (2017). CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database. Nucleic Acids Res. 45, D566–D573. doi: 10.1093/nar/gkw1004

Kaneshia, M., Sato, Y., Furumichi, M., Morishima, K., and Tanabe, M. (2019). New approach for understanding genome variations in KEGG. Nucleic Acids Res. 47, D590–D595. doi: 10.1093/nar/gky962

Kayer, F. H. (2003). Safety of Enterococci from the medical point of view. Int. J. Food Microbiol. 88, 255–262. doi: 10.1016/S0168-1605(03)00188-0

Kedare, S. B., and Singh, R. P. (2011). Genesis and development of DPPH method of antioxidant assay. J. Food Sci. Technol. 48, 412–422. doi: 10.1017/s13197-011-0251-1

Khan, H., Flint, S., and Yu, P. L. (2010). Enterocins in food preservation. Int. J. Food Microbiol. 141, 1–10. doi: 10.1016/j.ifoodmicro.2010.02.031

Klare, I., Konstabel, C., Badshtüber, D., Werner, G., and Witte, W. (2003). Occurrence and spread of antibiotic resistances in Enterococcus faecium. Int. J. Food Microbiol. 88, 269–290. doi: 10.1016/S0168-1605(03)00190-9

Kreuzer, S., Machnowska, P. A., Almus, J., Sieber, M., Pieper, R., Schmidt, M. F., et al. (2012). Feeding of the probiotic bacterium Enterococcus faecium NCIMB 10415 differentially affects shedding of enteric viruses in pigs. Vet. Res. 43:58. doi: 10.1186/1297-9716-43-58

Ladero, V., Linares, D. M., Del Rio, B., Fernandez, M., Martin, M. C., and Alvarez, M. A. (2013). Draft genome sequence of the tyramine producer Enterococcus durans strain IPLA 655. Genome Announc. 1:e00265-13. doi: 10.1128/genomeA.00265-13

Lam, M. C. M., Seemann, T., Bulach, D. M., Gladman, S. L., Chen, H., Haring, V., et al. (2012). Comparative analysis of the first complete Enterococcus faecium genome. J. Bacteriol. 194, 2334–2341. doi: 10.1128/JB.00259-12

Leavis, H. L., Bonten, M. J., and Willems, R. J. (2006). Identification of high-risk enterococcal clonal complexes: global dispersion and antibiotic resistance. Curr. Opin. Microbiol. 9, 454–460. doi: 10.1016/j.mib.2006.07.001

Li, B., Eivivie, S. E., Jin, D., Meng, Y., Li, N., Yan, F., et al. (2018a). Complete genome sequence of Enterococcus durans KLD56.0933, a potential probiotic strain with high cholesterol removal ability. Gut Pathog. 10:32. doi: 10.1186/s13099-018-0260-6

Li, B., Zhan, M., Eivivie, S. E., Jin, D., Zhao, L., Chowdhury, S., et al. (2018b). Evaluating the safety of potential probiotic Enterococcus durans KLD56.0930 using whole genome sequencing and oral toxicity study. Front. Microbiol. 9:1943. doi: 10.3389/fmicb.2018.01943

Linares, D. M., Fernández, M., Del-Rio, B., Ladero, V., Martin, M., and Alvarez, M. A. (2012). The tyrosyl-tRNA synthetase like gene located in the tyramine producing Enterococcus faecium strain. BMC Genom. 13:e234. doi: 10.1186/1471-2180-12-23

Liu, F., Li, B., Du, J., Yu, S., Li, W., Eivivie, S. E., et al. (2016). Complete genome sequence of Enterococcus durans KLD56.0930, a strain with probiotic properties. J Biotechnol. 217, 49–50. doi: 10.1016/j.jbiotec.2015.11.012

Ludwig, W., Schleifer, K.-H., and Whitman, W. B. (2001). Identification of high-risk enterococci isolated from dairy products: a review of risks and potential technological use. J. Food Prot. 64, 732–738. doi: 10.3150/96-02X-60.6.732

Marraffini, L. A., and Sontheimer, E. J. (2008). CRISPR interference limits horizontal gene transfer in Staphylococci by targeting DNA. Science 322, 1843–1845. doi: 10.1126/science.1165771

Murray, B. E. (2000). Vancomycin-resistant Enterococcal infections. N. Engl. J. Med. 342, 710–721. doi: 10.1056/NEJM20000309341007

Murray, B. E. (2000). Vancomycin-resistant Enterococcal infections. N. Engl. J. Med. 342, 710–721. doi: 10.1056/NEJM20000309341007

Murray, B. E. (2000). Vancomycin-resistant Enterococcal infections. N. Engl. J. Med. 342, 710–721. doi: 10.1056/NEJM20000309341007

Frontiers in Microbiology | www.frontiersin.org 15 December 2020 | Volume 11 | Article 608314

Hussein et al.

Enterococcus durans: Safety and Probiotic Traits

Hussein, W. E., Xiaoal, L., and Yousuf, A. E. (2019). Draft genome sequence of Enterococcus durans OSY-EYG, a multiple-antimicrobial-peptide producer isolated from Egyptian hard cheese. Microbiol. Resour. Announc. 8:e0303-19.
Murray, B. E., and Weinstock, G. M. (1999). Enterococci: new aspects of an old organism. *Proc. Assoc. Am. Phys. Med.* 111, 328–334. doi: 10.1046/j.1525-1381.1999.99241.x

Nami, Y., Abdullah, N., Haghshenas, B., Radiah, D., Rosli, R., and Khoroushshai, A. Y. (2014). Probiotic assessment of *Enterococcus durans* 6HL and *Lactococcus lactis* 2HL isolated from vaginal microflora. *J. Med. Microbiol.* 63, 1044–1051. doi: 10.1099/jmm.0.074161-0

Nami, Y., Vaseghi Bakshshayesh, R., Mohammadzadeh Jalaly, H., Lofti, H., Eslami, S., and Hejazi, M. A. (2019). Probiotic properties of *Enterococcus* isolated from artisanal dairy products. *Front. Microbiol.* 10:300. doi: 10.3389/fmicb.2019.00300

Natarajan, P., and Parani, M. (2015). First complete genome sequence of a probiotic *Enterococcus faecium* strain T-110 and its comparative genome analysis with pathogenic and non-pathogenic *Enterococcus faecium* genomes. *J. Genet. Genom.* 42, 43–46. doi: 10.1016/j.jgg.2014.07.002

Paulsen, I. T., Banerjei, L., Myers, G. S. A., Nelson, K. E., Seshadri, R., Read, T. D., Pillar, C. M., and Gilmore, M. S. (2004). Complete genome sequence of *Enterococcus faecalis* strain TX16 and comparative genomic analysis of *Enterococcus faecium* genomes. *BMC Microbiol.* 12:135. doi: 10.1186/1471-2180-12-135

Pilmar, C. M., and Gilmore, M. S. (2004). *Enterococcus* virulence - pathogenicity island of *Enterococcus faecium*. *Front. Biosci.* 9, 2335–2346. doi: 10.2741/1400

Qin, X., Galloway-Peña, J. R., Sillanpaa, J., Roh, J. H., Nallapareddy, S. R., Chowdhury, S., et al. (2012). Complete genome sequence of *Enterococcus faecium* strain TX16 and comparative genomic analysis of *Enterococcus faecium* genomes. *BMC Microbiol.* 12:135. doi: 10.1186/1471-2180-12-135

Ramos, C. L., Thorsen, L., Schwan, R. F., and Jespersen, L. (2013). Strain-specific probiotic properties of *Lactobacillus fermentum*, *Lactobacillus plantarum* and *Lactobacillus brevis* isolates from Brazilian food products. *Food Microbiol.* 36, 22–29. doi: 10.1016/J.FM.2013.03.010

Rosenberg, M., Gutnick, D., and Rosenberg, E. (1980). Adherence of bacteria to hydrocarbons: a simple method for measuring cell-surface hydrophobicity. *FEMS Microbiol. Lett.* 9, 29–33. doi: 10.1111/j.1574-6968.1980.tb0599.x

Rudel, L. L., and Morris, M. D. (1973). Determination of cholesterol using o-phenaldehyde. *J. Lipid Res.* 14, 364–371.

Ruiz-Garbajosa, P., Bonten, M. J. M., Robinson, D. A., Top, J., Nallapareddy, S. R., Torres, C., et al. (2006). Multilocus sequence typing scheme for *Enterococcus faecalis* reveals hospital-adapted genetic complexes in a background of high rates of recombination. *J. Clin. Microbiol.* 44, 2220–2228. doi: 10.1128/JCM.02596-05

Salminen, S., Ouwehand, A. C., and Isolauri, E. (1998). Clinical applications of probiotic bacteria. *Int. Dairy J.* 8, 563–572. doi: 10.1016/S0958-6946(98)0077-6

Sanders, M. E., Akkermans, L. M. A., Haller, D., Hammerman, C., Heimbach, J., Hörmannsperger, G., et al. (2010). Safety assessment of probiotics for human use. *Gut Microbiol.* 1, 164–185. doi: 10.4161/gmi.1.3.121127

Serio, A., Chaves-López, C., Paparella, A., and Suzzi, G. (2010). Evaluation of metabolic activities of *Enterococci* isolated from pecorino abruzzese cheese. *Int. Dairy J.* 20, 459–464. doi: 10.1016/j.idairyj.2010.02.005

Su, Y. A., Sulavik, M. C., He, P., Makinen, K. K., Makinen, P. L., Fiedler, S., et al. (1991). Nucleotide sequence of the gelatinase gene (gelE) from *Enterococcus faecalis* subsp. liquefaciens. * Infect. Immun.* 59, 415–420. doi: 10.1128/iai.59.1.415-420.1991

Suvorov, A., Ermolenko, A., Alechina, G., Chernysh, A., Karaseva, A., Di Pierro, F., et al. (2019). *Enterococcus* as probiotics: what is the advantage? *Nutrofoods* 1, 17–25. doi: 10.17470/NF-019-0003

Thompson, T., and Marth, E. (1986). Changes in Parmesan cheese during ripening: microflora - coliforms, *Enterococcus*, anaerobes, *Propionibacteria* and *Staphylococci*. *Milchwissenschaft* 41, 201–205.

Ubeda, C., Taur, Y., Jenq, R. R., Equinda, M. J., Son, T., Samstein, M., et al. (2010). Vancomycin-resistant *Enterococcus* dominance of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. *J. Clin. Invest.* 120, 4332–4341. doi: 10.1172/JCI43918

van Reenen, C. A., and Dicks, L. M. T. (2011). Horizontal gene transfer amongst probiotic lactic acid bacteria and other intestinal microbiota: what are the possibilities? *A review. Arch. Microbiol.* 193, 157–168. doi: 10.1007/s00203-010-0686-3

van Schaik, W., Top, J., Riley, D. R., Boekhorst, J., Vrijenhoek, J. E. P., Schapendonk, C. M. E., et al. (2010). Pyrosequencing-based comparative genome analysis of the nosocomial pathogen *Enterococcus faecium* and identification of a large transferable pathogenicity island. *BMC Genomics* 11:239. doi: 10.1186/1471-2164-11-239

Walker, D. K., and Gilliland, S. E. (1993). Relationship among bile tolerance, bile salt deconjugation, and assimilation of cholesterol by *Lactobacillus acidophilus*. *J. Dairy Sci.* 76, 956–961. doi: 10.3168/jds.S0022-0302(93)77422-6

Walsh, C. J., Guinane, C. M., Hill, C., Ross, R. P., O’toole, P. W., and Cotter, P. D. (2011). In silico identification of bacteriocin gene clusters in the gastrointestinal tract, based on the Human Microbiome Project’s reference genome database. *BMC Microbiol.* 15:183. doi: 10.1186/1471-2164-11-183

Wang, Y., Wu, Y., Wang, Y., Xu, H., Mei, X., Yu, D., et al. (2017). Antioxidant properties of probiotic bacteria. *Nutrients* 9:521. doi: 10.3390/nu9050521

Wassenaar, T., Zschüttig, A., Beimfohr, C., Geske, T., Auerbach, C., Cook, H., et al. (2015). Virulence genes in a probiotic *Escherichia coli* product with a recorded long history of safe use. *Eur. J. Microbiol. Immunol.* 5, 81–93. doi: 10.1556/EuMI-D-14-00039

Werner, G., Fleige, C., Geringer, U., van Schaik, W., Klare, I., and Witte, W. (2011). IS element IS16 as a molecular screening tool to identify hospital-associated strains of *Enterococcus faecium*. *BMC Infect. Dis.* 11:80. doi: 10.1186/1471-2334-11-80

Wilkner, M. A., Lamp, D. E., Cockrell, F. R., Sheehan, D. J., Craig, W. A., Tenover, F. C., et al. (2006). Methods for Dilation Antimicrobial Susceptibility Tests for *Bacteria that Grow Aerobically: Approved Standard*. Wayne, PA: Clinical and Laboratory Standards Institute.

Xu, H., Jeong, H. S., Lee, H. Y., and Ahn, J. (2009). Assessment of cell surface properties and adhesion potential of selected probiotic strains. *Lett. Appl. Microbiol.* 49, 434–442. doi: 10.1111/j.1472-765X.2009.02684.x

Zhong, Z., Zhang, W., Song, Y., Liu, W., Xu, H., Xi, X., et al. (2017). Comparative genomic analysis of the genus *Enterococcus*. *Microbiol. Res.* 196, 95–105. doi: 10.1016/J.MICRES.2016.12.009

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.